Crossmark

Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

Crossref DOI link: https://doi.org/10.1186/s13075-019-1976-x

Published Online: 2019-09-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liang, Nan

Sun, Mingshu

Sun, Ruixia

Xu, Ting

Cui, Lingling

Wang, Can

Ma, Lidan

Cheng, Xiaoyu

Xue, Xiaomei

Sun, Wenyan

Yuan, Xuan

Zhang, Hui

Li, Hailong

He, Yuwei

Ji, Aichang

Wu, Xinjiang

Li, Changgui https://orcid.org/0000-0002-4622-3731
Funding

Funding for this research was provided by:

National Key Research and Development Program of China (2016YFC0903400)

National Natural Science Foundation of China (81520108007, 31471195, 81602258)

National Natural Science Foundation of China (81770869)

Shandong Province Key Research and Development Program (2018CXGC1207)

Natural Science Foundation of Shandong Province (ZR2018ZC1053)

the Basic Application Research Plan of Qingdao (15-9-1-98-jch)
License Information

Text and Data Mining valid from 2019-09-02

Version of Record valid from 2019-09-02
More Information

Article History

Received: 27 January 2019

Accepted: 16 August 2019

First Online: 2 September 2019

Ethics approval and consent to participate

: The study was approved by the ethics committee of Affiliated Hospital of Qingdao University, and informed consents were obtained from all patients.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below